SuperworthCharles River Laboratories International profit margin CRL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- −6.0%
- Operating margin, 12 months
- 2.3%
- Net margin on a year earlier
- −4.3 pts
- Peer median
- 14.1%
Over the twelve months to Jun 27, 2026, Charles River Laboratories International kept −6.0% of its revenue as net profit, with an operating margin of 2.3% and a gross margin of 32.7%.
Five years earlier its net margin was 12.1%.
The median for 10 diagnostics and research stocks of a similar size is 14.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −3.6% | 0.6% | 33.0% |
| FY2024 | 0.5% | 5.6% | 32.9% |
| FY2023 | 11.5% | 14.9% | 36.4% |
| FY2022 | 12.2% | 16.4% | 36.8% |
| FY2021 | 11.0% | 16.7% | 37.7% |
| FY2020 | 12.5% | 14.8% | 36.7% |
| FY2019 | 9.6% | 13.4% | 36.6% |
| FY2018 | 10.0% | 14.6% | 37.1% |
| FY2017 | 6.6% | 15.5% | 37.7% |
| FY2016 | 9.2% | 14.1% | 38.5% |
| FY2015 | 11.0% | 15.1% | 39.0% |
| FY2014 | 9.8% | 13.7% | 36.4% |
| FY2013 | 8.8% | 13.0% | 24.2% |
| FY2012 | 8.6% | 14.7% | 35.0% |
| FY2011 | 9.6% | 15.3% | 35.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −6.0% | −4.3 pts | 2.3% | |
| Q1 FY26 | −4.6% | −4.0 pts | 1.7% | |
| Q4 FY25 | −3.6% | −4.1 pts | 0.6% | |
| Q3 FY25 | −2.0% | −12.5 pts | 3.5% | |
| Q2 FY25 | −1.7% | −12.5 pts | 3.1% | |
| Q1 FY25 | −0.6% | −11.4 pts | 4.4% | |
| Q4 FY24 | 0.5% | −10.9 pts | 5.6% | |
| Q3 FY24 | 10.4% | −0.8 pts | 13.0% | |
| Q2 FY24 | 10.8% | −0.8 pts | 13.8% | |
| Q1 FY24 | 10.8% | −1.3 pts | 14.0% | |
| Q4 FY23 | 11.5% | −0.7 pts | 14.9% | |
| Q3 FY23 | 11.3% | −0.3 pts | 15.4% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Charles River Laboratories International's size, closest first, today.
| Company | Profit margin |
|---|---|
| CRLCharles River Laboratories International | −6.0% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| BIOBio-Rad Laboratories | 8.6% |
| CAICaris Life Sciences | 10.6% |
| MTDMettler-Toledo International | 21.9% |
| ILMNIllumina | 18.4% |
| LNTHLantheus | 17.7% |
| IDXXIDEXX Laboratories | 25.0% |
| Peer median | 14.1% |
Where Charles River Laboratories International ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Charles River Laboratories International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.